Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 111716003 | 11171600 | 3 | F | 2015 | 20160713 | 20150608 | 20160721 | EXP | US-SA-2014SA084581 | AVENTIS | 58.00 | YR | A | M | Y | 0.00000 | 20160721 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 111716003 | 11171600 | 1 | PS | AUBAGIO | TERIFLUNOMIDE | 1 | Oral | UNKNOWN | 202992 | 14 | MG | QD | |||||||
| 111716003 | 11171600 | 2 | SS | AMPYRA | DALFAMPRIDINE | 1 | Oral | UNK | 0 | 10 | MG | TABLET | BID | ||||||
| 111716003 | 11171600 | 3 | SS | TYSABRI | NATALIZUMAB | 1 | Unknown | U | UNK | 0 | |||||||||
| 111716003 | 11171600 | 4 | C | TOPROL XL | METOPROLOL SUCCINATE | 1 | 0 | ||||||||||||
| 111716003 | 11171600 | 5 | C | CELEXA | CITALOPRAM HYDROBROMIDE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 111716003 | 11171600 | 1 | Multiple sclerosis |
| 111716003 | 11171600 | 2 | Gait disturbance |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 111716003 | 11171600 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 111716003 | 11171600 | Balance disorder | |
| 111716003 | 11171600 | Condition aggravated | |
| 111716003 | 11171600 | Confusional state | |
| 111716003 | 11171600 | Drug dose omission | |
| 111716003 | 11171600 | Fatigue | |
| 111716003 | 11171600 | Head discomfort | |
| 111716003 | 11171600 | Hepatitis C | |
| 111716003 | 11171600 | Hypoaesthesia | |
| 111716003 | 11171600 | Inappropriate schedule of drug administration | |
| 111716003 | 11171600 | Infection susceptibility increased | |
| 111716003 | 11171600 | JC virus test positive | |
| 111716003 | 11171600 | Memory impairment | |
| 111716003 | 11171600 | Mental impairment | |
| 111716003 | 11171600 | Micturition urgency | |
| 111716003 | 11171600 | Muscle spasms | |
| 111716003 | 11171600 | Muscular weakness | |
| 111716003 | 11171600 | Temperature intolerance | |
| 111716003 | 11171600 | Visual acuity reduced |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 111716003 | 11171600 | 1 | 20140523 | 0 | ||
| 111716003 | 11171600 | 2 | 20110214 | 0 |